Peripartum cardiomyopathy: Update 2012

Current Opinion in Critical Care

Volumn 19, Issue 5, 2013, Pages 397-403

  Bachelier Walenta, Katrin ^a   Hilfiker Kleiner, Denise ^b   Sliwa, Karen ^c  

^a SAARLAND UNIVERSITY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Heart failure; Peripartum cardiomyopathy; Pregnancy

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BROMOCRIPTINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INOTROPIC AGENT; PROLACTIN; REMIFENTANIL; VASODILATOR AGENT;

CARDIAC RESYNCHRONIZATION THERAPY; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART OUTPUT; HEART TRANSPLANTATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERCOAGULABILITY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LEFT VENTRICULAR ASSIST DEVICE; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MORBIDITY; MORTALITY; OXIDATIVE STRESS; PERIPARTUM CARDIOMYOPATHY; PREGNANCY; PROGNOSIS; PROSPECTIVE STUDY; PUERPERIUM; PULMONARY ARTERY OCCLUSION PRESSURE; REVIEW; RISK FACTOR; VASCULAR DISEASE;

CARDIAC OUTPUT; CARDIOMYOPATHIES; FEMALE; HUMANS; PERIPARTUM PERIOD; PREGNANCY; PROGNOSIS; PUERPERAL DISORDERS; PULMONARY WEDGE PRESSURE; RISK FACTORS;

EID: 84885022621     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e328364d7db     Document Type: Review

References (55)

1. Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010; 12:767-778.
2. Mielniczuk LM, Williams K, Davis DR, et al. Frequency of peripartum cardiomyopathy. Am J Cardiol 2006; 97:1765-1768.
3. Desai D, Moodley J, Naidoo D. Peripartum cardiomyopathy: experiences at King Edward VIII Hospital, Durban, South Africa and a review of the literature. Trop Doct 1995; 25:118-123.
4. Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc 2005; 80:1602-1606.
5. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007; 128:589-600.
6. Hilfiker-Kleiner D, Knoll R. Disease-modifying mutations in familial hypertrophic cardiomyopathy: complexity from simplicity. Circulation 2008; 117:1775-1777.
7. Hilfiker-Kleiner D, Meyer GP, Schieffer E, et al. Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J Am Coll Cardiol 2007; 50:2354-2355.
8. Sliwa K, Blauwet L, Tibazarwa K, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 2010; 121:1465-1473.
9. Patten IS, Rana S, Shahul S, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 2012; 485:333-338.
10. Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet 2006; 368:687-693.
11. Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J Am Coll Cardiol 2011; 58:659-670.
12. Sliwa K, Carrington M, Mayosi BM, et al. Incidence and characteristics of newly diagnosed rheumatic heart disease in urban African adults: insights from the Heart of Soweto study. Eur Heart J 2010; 31:719-727.
13. Ntusi NB, Mayosi BM. Aetiology and risk factors of peripartum cardiomyopathy: a systematic review. Int J Cardiol 2009; 131:168-179.
14. Morales A, Painter T, Li R, et al. Rare variant mutations in pregnancyassociated or peripartum cardiomyopathy. Circulation 2010; 121:2176-2182.
15. Walenta K, Schwarz V, Schirmer S, et al. Circulating microparticles as indicators of peripartum cardiomyopathy. Eur Heart J 2012; 33:1469-1479.
16. Halkein J, Tabruyn SP, Ricke-Hoch M, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest 2013; 123:2143-2154.
17. Blauwet LA, Cooper LT. Diagnosis and management of peripartum cardiomyopathy. Heart 2011; 97:1970-1981.
18. Sliwa K, Wilkinson D, Hansen C, et al. Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto study): a cohort study. Lancet 2008; 371:915-922.
19. Nishimoto O, Matsuda M, Nakamoto K, et al. Peripartum cardiomyopathy presenting with syncope due to Torsades de pointes: a case of long QT syndrome with a novel KCNH2 mutation. Intern Med 2012; 51:461-464.
20. Horne BD, Rasmusson KD, Alharethi R, et al. Genome-wide significance and replication of the chromosome 12p11.22 locus near the PTHLH gene for peripartum cardiomyopathy. Circ Cardiovasc Genet 2011; 4:359-366.
21. Russell RB, Petrini JR, Damus K, et al. The changing epidemiology of multiple births in the United States. Obstet Gynecol 2003; 101:129-135.
22. Elkayam U, Akhter MW, Singh H, et al. Pregnancy-Associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation 2005; 111:2050-2055.
23. Brar SS, Khan SS, Sandhu GK, et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol 2007; 100:302-304.
24. Lampert MB, Hibbard J, Weinert L, et al. Peripartum heart failure associated with prolonged tocolytic therapy. Am J Obstet Gynecol 1993; 168:493-495.
25. Kamiya CA, Kitakaze M, Ishibashi-Ueda H, et al. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders: results from the Japanese Nationwide survey of peripartum cardiomyopathy. Circ J 2011; 75:1975-1981.
26. Blauwet LA, Libhaber E, Forster O, et al. Predictors of outcome in 176 South African patients with peripartum cardiomyopathy. Heart 2013; 99:308-313.
27. Duran N, Gunes H, Duran I, et al. Predictors of prognosis in patients with peripartum cardiomyopathy. Int J Gynaecol Obstet 2008; 101:137-140.
28. Endorsed by the European Society of Gynecology (ESG), the Association for European Paediatric Cardiology (AEPC), and the German Society for Gender Medicine (DGesGM); Authors/Task Force Members, Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011. doi:10.1093/eurheartj/ehr218.
29. Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost 2003; 29:125-130.
30. Diao M, Diop IB, Kane A, et al. Electrocardiographic recording of long duration (Holter) of 24 h during idiopathic cardiomyopathy of the peripartum. Arch Mal Coeur Vaiss 2004; 97:25-30.
31. Saltzberg MT, Szymkiewicz S, Bianco NR. Characteristics and outcomes of peripartum versus nonperipartum cardiomyopathy in women using a wearable cardiac defibrillator. J Card Fail 2012; 18:21-27.
32. Zimmerman H, Bose R, Smith R, et al. Treatment of peripartum cardiomyopathy with mechanical assist devices and cardiac transplantation. Ann Thorac Surg 2010; 89:1211-1217.
33. Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J 2006; 152:509-513.
34. Habli M, OBrien T, Nowack E, et al. Peripartum cardiomyopathy: prognostic factors for long-term maternal outcome. Am J Obstet Gynecol 2008; 199:415.e1-e5.
35. Rasmusson KD, Budge D, Alharethi R, et al. Long-term outcomes in patients with peripartum cardiomyopathy and no recovery of left ventricular function. J Card Fail 2010; 16:S97.
36. Jahns B, Stein W, Hilfiker-Kleiner D, et al. Peripartum cardiomyopathy: a new treatment option by inhibition of prolactin secretion. Am J Obstet Gynecol 2008; 199:e5-e6.
37. Fett JD. Caution in the use of bromocriptine in peripartum cardiomyopathy. J Am Coll Cardiol 2008; 51:2083.
38. Hilfiker-Kleiner D, Struman I, Hoch M, et al. 16-kDa prolactin and bromocriptine in postpartum cardiomyopathy. Curr Heart Fail Rep 2012; 9:174-182.
39. Krause T, Lovibond K, Caulfield M, et al. Management of hypertension: summary of NICE guidance. BMJ 2011; 343:d4891.
40. Bullo M, Tschumi S, Bucher BS, et al. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension 2012; 60:444-450.
41. Meidahl Petersen K, Jimenez-Solem E, Andersen JT, et al. b-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population- based cohort study. BMJ Open 2012; 19
42. Indira K, Sanjeev K, Sunanda G. Sequential combined spinal epidural anesthesia for caeserean section in peripartum cardiomyopathy. India J Anaesth 2007; 51:137-139.
43. Ecker JL, Frigoletto FD Jr. Cesarean delivery and the risk-benefit calculus. N Engl J Med 2007; 356:885-888.
44. Kaufman I, Bondy R, Benjamin A. Peripartum cardiomyopathy and thromboembolism: anesthetic management and clinical course of an obese diabetic patient. Can J Anaesth 2003; 50:161-165.
45. McCarroll CP, Paxton LD, Elliott P, Wilson DB. Use of remifentanyl in a patient with peri-partum cardiomyopathy requiring caesarean section. Br J Anaesth 2001; 86:135-138.
46. Peng TC, Chuah EC. Peripartum cardiomyopathy: a case report. Acta Anaesthesiol Sin 2001; 39:47-51.
47. Domenech Asensi P, Hernundez-Palazon J, Tortosa Serrano J, et al. Puerperal cardiomyopathy and pulmonary edema after caesarean section. Rev Esp Anestesiol Reanim 2002; 49:156-159.
48. Osinaike B, Ogah J. Anaesthesia for emergency caesarean section in a patient with peripartum cardiomypathy. Cardiovasc J Afr 2011; 22:337-340.
49. Shrestha BR, Thapa C. Peripartum cardiomyopathy undergoing caesarean section under epidural anaesthesia. Kathmandu Univ Med J 2006; 4:503-505.
50. Rasmusson KD, Budge D, Alharethi R, et al. Long-term outcomes in patients with peripartum cardiomyopathy and no recovery of left ventricular function. J Card Fail 2010; 16:S97.
51. Modi KA, Illum S, Jariatul K, et al. Poor outcome of indigent patients with peripartum cardiomyopathy in the United States. Am J Obstet Gynecol 2009; 201:171.e1-171.e15.
52. Goland S, Modi K, Hatamizadeh P, Elkayam U. Differences in clinical profile of African-American women with peripartum cardiomyopathy in the United States. J Card Fail 2013; 19:214-218.
53. Biteker M, Ilhan E, Biteker G, et al. Delayed recovery in peripartum cardiomyopathy: an indication for long-term follow-up and sustained therapy. Eur J Heart Fail 2012; 14:895-901.
54. Chapa JB, Heiberger HB, Weinert L, et al. Prognostic value of echocardiography in peripartum cardiomyopathy. Obstet Gynecol 2005; 105:1303-1308.
55. Sliwa K, Fo rster O, Libhaber E, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J 2006; 27:441-446.